High quality MOTS-c10 (Human) Acetate 99% Powder 1627580-64-6 peptide door to door

NAD

Adenosine 5′-(trihydrogen diphosphate),P′→5′-ester with 3-(aminocarbonyl)-1-β-D-ribofuranosylpyridinium,inner salt;Pyridinium,3-carbamoyl-1-β-D-ribofuranosyl-,hydroxide,5′→5′-ester with adenosine 5′-(trihydrogen pyrophosphate),inner salt;Adenosine 5′-(trihydrogen diphosphate),P′→5′-ester with 3-(aminocarbonyl)-1-β-D-ribofuranosylpyridinium hydroxide,inner salt;Codehydrase I;Codehydrogenase I;Coenzyme I;Diphosphopyridine nucleotide;DPN;Cozymase I;NAD;Nadide;Nicotinamide-adenine dinucleotide;Oxidized diphosphopyridine nucleotide;Adenine-nicotinamide dinucleotide;NAD+;Enzopride;β-NAD;β-Diphosphopyridine nucleotide;β-Nicotinamide adenine dinucleotide;β-NAD+;NSC 20272;CO-I;β-Nicotinamide adenine dinucleotide hydrate;30429-30-2;159929-29-0;1083039-67-1;1354693-98-3

53-84-9

C21H27N7O14P2

InChIKey=BAWFJGJZGIEFAR-NNYOXOHSSA-N

663.43

663.109131

200-184-4

757121

DTXSID2045236

C87339

29349990

Bulk Drug Intermediates

321

-1.29620

White Powder

140-142 °C (decomp)

soluble in water at 50mg/ml

2-8°C

D20 -31.5° (c = 1.2 in water)

226.7 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|227.5 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|222.7 Ų [M+Na]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|223.8 Ų [M-H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|230.8 Ų [M+Na-2H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|227 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

Mitochondrial-derived peptide (MDP), 16-amino-acid peptide

Research compound — Not FDA approved

MOTS-c (mitochondrial ORF of the twelve S rRNA-c) is a 16-amino-acid peptide encoded by the mitochondrial genome (not nuclear DNA). It is a mitochondrial-derived peptide that regulates metabolic homeostasis by activating the AMPK/PGC-1\u03b1 pathway, improving insulin sensitivity, and enhancing exercise capacity. MOTS-c crosses the blood-brain barrier and has been shown to reduce body weight and improve glucose tolerance in preclinical models.

MOTS-c does not act via a traditional receptor. It functions as a metabolic regulator, activating AMPK. Functional effects are observed at micromolar concentrations in cell-based assays.

Lee C, et al. Cell Metab. 2015;21(3):443-454. MCE: MOTS-c (CAS 1627580-64-6).DOI

PubChem

MCE: MOTS-c (CAS 1627580-64-6); Cell Metab: Lee C, et al. (2015) — MOTS-c discovery

MOTS-c is NOT FDA-approved or EMA-approved. It is a research compound only. All data are from preclinical (cell/animal) studies; no human clinical trials have been completed. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.